Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Organon & Co. Common Stock — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.91 (market cap $3.69B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares MSCI United Kingdom (FTSE) and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 48 Days and Organon & Co. Common Stock for 0 Days on average.
| EWU | OGN | |
|---|---|---|
Market Cap | $3.69B | $3.62B |
Volume | 701,016 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $13.81 |
52-Week Low | $41.34 | $5.70 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.82 with a modest 0.26% daily gain, though technical indicators signal a bearish trend with moving averages and overall momentum pointing downward. The stock faces headwinds from UK economic concerns including rising gilt yields and inflation pressures. Recent news highlights sector-specific volatility in UK banking and housing markets, creating a challenging environment for this UK-focused ETF.
The outlook remains cautious given macroeconomic pressures on UK assets. Investment opportunity exists for contrarian investors betting on UK recovery, but risks include persistent inflation, rising interest rates, and political uncertainty around upcoming budget decisions that could impact financial and housing sectors significantly.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
